百奥泰(688177)：公司近况跟踪(一)

Group 1 - Company BAT1308 injection combined with BAT4706 injection and BAT8008 injection has received clinical trial approval for the treatment of advanced solid tumors [1] - BAT1308 is a humanized anti-PD-1 monoclonal antibody with high affinity for human PD-1, while BAT4706 targets CTLA-4 and is an IgG1 fully human monoclonal antibody [1] - BAT8008 is an antibody-drug conjugate targeting Trop2, demonstrating high anti-tumor activity and stability in plasma with a low shedding rate [1] Group 2 - BAT5906 has received approval for multiple clinical trials, including indications for w-AMD, DME, CRVO-ME, and pmCNV [2] - The company has completed Phase I, II, and III clinical studies for w-AMD, and the majority of patient recruitment for Phase III studies for DME has been completed [2] - The company is expected to achieve revenues of 889 million, 1.131 billion, and 1.699 billion yuan from 2025 to 2027, with a projected net profit of -459 million, -379 million, and 5 million yuan [2]